LULU — Lululemon Athletica Inc.

Q2 FY2026 (reported 2026-09-03) missed badly: revenue fell ~4% YoY to $2.42B, global comparable sales dropped 9%, and Americas comps plunged 12%. Management cut FY2026 guidance for the second straight quarter (revenue $10.35-10.50B, -5% to -7%; EPS $9.48-9.73) and guided Q3 revenue down 10-11%. Shares fell ~17-18% to the ~$98-101 area, an eight-year low. The FMP analyst panel (12 firms) shows a 'Hold' consensus with a $97.67 mean target (high $115, low $70), and JPMorgan cut its target toward $95. New CEO Heidi O'Neill (ex-Nike) took over 2026-09-08 into a depleted executive bench, and Levi & Korsinsky opened a securities investigation. Sentiment is defensively bearish, with a minority 'fat pitch' contrarian camp (e.g. Michael Burry) citing the debt-free balance sheet.

A clear, multi-quarter deceleration and margin compression - not a blip. Revenue growth went from ~20%+ in 2023 to +7.1% YoY in Q3 FY2025 (rev $2.566B vs $2.397B), ~flat (+0.8%) in Q4 FY2025 (rev $3.641B vs $3.612B), and negative (-4.3%) in Q2 FY2026 (rev $2.416B vs $2.525B). Operating margins have compressed in step: Q4 op income fell from $1.042B (28.9% margin) to $803.5M (22.1%); Q2 op income fell from $523.8M (20.7%) to $453.7M (18.8%). Q1 FY2026 was the worst - revenue rose 4.3% ($2.472B vs $2.371B) but operating income fell 36.9% ($276.9M vs $438.6M, an 11.2% margin, likely hit by charges/tariff effects), and diluted EPS fell to $1.69 from $2.60. Diluted EPS: Q2 $2.92 (from $3.10), Q1 $1.69 (from $2.60), Q4 $4.97 (from $6.14), Q3 $2.59 (from $2.87). TTM EPS is $12.56 and consensus FY2026E EPS is $9.70 - the company is guiding its own earnings down ~20%+ this year. This is structural deceleration in the Americas masked by international growth that is now also slowing.

Cheap vs. its own history - but not obviously cheap vs. its deteriorating fundamentals. As of 2026-09-13 the stock trades at 8.13x TTM EPS ($12.56), ~10.2x the $9.70 consensus FY2026 EPS, 1.01x sales, ~4.7x EV/EBITDA, 2.33x book and a ~12% TTM FCF yield, versus a 5-year average P/E of 34.08 and P/S of 4.95 - a historic de-rating. But PEG is -0.468 precisely because earnings are shrinking, so the low absolute multiple is partly rational, not purely a mispricing. The deterministic model's "Cheap vs. its own history" label is accurate on its own terms; the question is whether a structural decliner deserves even 10x forward earnings.

The market has stopped paying for growth: at ~10x forward EPS and a ~12% FCF yield, the price already embeds a lasting mid-single-digit revenue decline. Two readings. (1) If FY2026's $9.48-9.73 is the trough and Americas comps stabilize in FY2027, the stock is underpricing a recovery, and even a modest re-rate to 13-14x would be worth 25%+ from $98.97. (2) If the -9% global comps keep deteriorating and FY2027 EPS is revised toward $8, today's 'cheap' 10x is really 12x with more downside. The discriminator is the Q3 FY2026 print (~Dec 2026): does the -10% to -11% guide prove to be the bottom, or a waypoint? Until then, the estimate itself is the risk, not the multiple.

As of 2026-09-13, RSI(14) is 33.94 - weak, but not yet classic oversold (<30). Price is 13.31% below the 20-day SMA, 15.5% below the 50-day and 34.65% below the 200-day, all steadily trending down with no flattening. Returns: -1.63% (1wk), -18.12% (1mo), -16.67% (3mo), -37.27% (6mo). At $98.97 against a 52-week range of $95.67-$225.98, this is a falling knife, not a base. Entry-timing implication: wait for a reclaim of the 20-day SMA or a positive RSI divergence before treating the oversold reading as actionable; buying purely on the P/E is how value traps are entered.

• Consumer discretionary pressure on middle- and high-income households compressing discretionary apparel spend.
• Athleisure market saturation in North America, with domestic share loss to Alo Yoga, Vuori and Fabletics.
• China deceleration - soft store traffic, negative online commentary and shifting consumer sentiment in what had been a key growth market.
• Tariffs and input costs pressuring gross margin; Q2 gross margin was helped by a discrete $134.5M tariff refund, so baseline profitability faces promotional-discounting risk.
• Sector rotation and rate sentiment weighing on premium-multiple consumer names, amplifying the de-rating of a high-growth-to-low-growth transition story.

• Q3 FY2026 earnings (~Dec 2026) - first concrete test of the -10% to -11% revenue guide and whether Americas comps bottom.
• New CEO Heidi O'Neill's initial strategy, restructuring and capital-allocation plan.
• Possible buyback/dividend action given the debt-free balance sheet ($1.39B cash, zero long-term debt) and depressed valuation.
• International/China trajectory and any stabilization in North American store traffic.
• Developments in the Levi & Korsinsky securities investigation announced post-guidance-cut.

• Structural, not cyclical, market-share loss - if Alo/Vuori/Fabletics keep taking share, both the growth input and the multiple have further to fall.
• Continued guidance cuts and FY2027 EPS downgrades that make today's ~10x forward multiple not actually cheap.
• Margin compression from deeper promotions to clear inventory, compounded by tariff cost and the loss of the one-off $134.5M tariff refund.
• Executive turnover and execution risk under a brand-new CEO inheriting a depleted bench.
• Persistent negative momentum - the stock is down over 50% YTD and 34.65% below its 200-day; value traps can stay cheap for years.

Genuine quality (22.7% ROIC, 56% gross margin, zero long-term debt, ~12% TTM FCF yield, 89.8 financial-health score) meets a genuine growth wall: revenue down 4% YoY, global comps down 9%, Americas comps down 12%, and a second guidance cut. At ~10x forward EPS, much of the bad news is likely priced in, and the debt-free balance sheet gives management real optionality. But the evidence points more to structural competitive share loss than a cyclical trough about to turn, and there is zero technical evidence of a base. Not a buy at $98.97 - the honest position is to wait for a comps bottom (Q3 print) or a technical base before committing capital.

Applied a forward P/E of ~12.5x to consensus FY2026E EPS of $9.70 (the midpoint of management's $9.48-9.73 guidance), giving ~$121. The multiple is far below the 5-year average P/E of 34.08 (a hyper-growth multiple no longer warranted) but above a generic no-growth retailer's, justified by the debt-free balance sheet, 22.7% ROIC, 56% gross margin and ~12% TTM FCF yield, and capped by negative comps and competitive share loss. Cross-check: ~$1.35B TTM free cash flow against an ~$9.85B EV implies ~7.3x EV/FCF, consistent with a low-to-mid-teens earnings multiple rather than a distressed one.